伊伯多米德增加了复发性/耐药性多发性髓瘤患者骨髓中的先天性和适应性免疫细胞子集

Oliver Van Oekelen1, Michael Amatangelo2, Manman Guo3

  • 1Department of Medicine, Mount Sinai Beth Israel, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PubMed
概括

伊伯多米德治疗显著增强了多发性骨髓瘤患者的T细胞和NK细胞等免疫细胞. 这些免疫变化与治疗反应相关,并表明伊伯多米德可以增强免疫系统对抗癌症.